Business Description
PharmAbcine Inc
ISIN : KR7208340000
Share Class Description:
XKRX:208340: Ordinary SharesCompare
Compare
Traded in other countries / regions
208340.Korea IPO Date
2018-11-21Description
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.68 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.77 | |||||
| Beneish M-Score | 2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.8 | |||||
| 3-Year EBITDA Growth Rate | 24.6 | |||||
| 3-Year EPS without NRI Growth Rate | 28.4 | |||||
| 3-Year FCF Growth Rate | 27.9 | |||||
| 3-Year Book Growth Rate | -37.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 55.85 | |||||
| 12-1 Month Momentum % | 192.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.6 | |||||
| Quick Ratio | 9.6 | |||||
| Days Sales Outstanding | 21.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.4 | |||||
| Shareholder Yield % | 4.08 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 24.46 | |||||
| Operating Margin % | -765.37 | |||||
| Net Margin % | -819.04 | |||||
| FCF Margin % | -1232.39 | |||||
| ROE % | -28.26 | |||||
| ROA % | -20.18 | |||||
| ROIC % | -28.71 | |||||
| ROC (Joel Greenblatt) % | -59.62 | |||||
| ROCE % | -23.52 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 135.55 | |||||
| PB Ratio | 5.21 | |||||
| Price-to-Tangible-Book | 5.21 | |||||
| EV-to-EBIT | -12.81 | |||||
| EV-to-EBITDA | -14.57 | |||||
| EV-to-Revenue | 100.21 | |||||
| EV-to-FCF | -8.13 | |||||
| Price-to-Net-Current-Asset-Value | 6.14 | |||||
| Earnings Yield (Greenblatt) % | -7.81 | |||||
| FCF Yield % | -10.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmAbcine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 744.176 | ||
| EPS (TTM) (â‚©) | -183.201 | ||
| Beta | 1.26 | ||
| Volatility % | 246.03 | ||
| 14-Day RSI | 55.85 | ||
| 14-Day ATR (â‚©) | 0.00003 | ||
| 20-Day SMA (â‚©) | 2915 | ||
| 12-1 Month Momentum % | 192.38 | ||
| 52-Week Range (â‚©) | 918 - 4630 | ||
| Shares Outstanding (Mil) | 80.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmAbcine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmAbcine Inc Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
PharmAbcine Inc Frequently Asked Questions
What is PharmAbcine Inc(XKRX:208340)'s stock price today?
The current price of XKRX:208340 is â‚©2915.00. The 52 week high of XKRX:208340 is â‚©4630.00 and 52 week low is â‚©918.00.
When is next earnings date of PharmAbcine Inc(XKRX:208340)?
The next earnings date of PharmAbcine Inc(XKRX:208340) is 2025-02-14 Est..
Does PharmAbcine Inc(XKRX:208340) pay dividends? If so, how much?
PharmAbcine Inc(XKRX:208340) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers